Monascuspiloin

Synonyms: Monascinol
Monascuspiloin (Monascinol) 是一种从红霉菌发酵大米中提取的具有口服活性的化合物,具有抗雄激素、抗炎、降血脂、抗癌等多种生物活性,可通过减弱 PI3K/Akt/mTOR 信号通路、增强 AMPK 磷酸化、下调 FASN/SREBP2 来诱导前列腺癌细胞发生凋亡 (apoptosis)、G2/M 期阻滞和自噬 (autophagy),干扰双氢睾酮 (dihydrotestosterone)-受体结合,增强辐射诱导的 DNA 损伤,刺激内质网应激,缓解肝脏氧化应激,调控肝脏代谢通路并调节肝脏脂质代谢相关基因和蛋白的表达,可用于前列腺癌和酒精性肝损伤的相关研究。
产品编号: MS-D50367 纯度: 95% CAS No.: 1011244-19-1 分子式: C21H28O5 分子量: 360.44
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
500μg
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价

产品描述

Monascuspiloin (Monascinol) 是一种从红霉菌发酵大米中提取的具有口服活性的化合物,具有抗雄激素、抗炎、降血脂、抗癌等多种生物活性,可通过减弱 PI3K/Akt/mTOR 信号通路、增强 AMPK 磷酸化、下调 FASN/SREBP2 来诱导前列腺癌细胞发生凋亡 (apoptosis)、G2/M 期阻滞和自噬 (autophagy),干扰双氢睾酮 (dihydrotestosterone)-受体结合,增强辐射诱导的 DNA 损伤,刺激内质网应激,缓解肝脏氧化应激,调控肝脏代谢通路并调节肝脏脂质代谢相关基因和蛋白的表达,可用于前列腺癌和酒精性肝损伤的相关研究。

生物实验数据

生物活性 Monascuspiloin (Monascinol) is an orally active compound extracted from red mold fermented rice that exhibits multiple biological activities including anti-androgenic, anti-inflammatory, lipid-lowering, and anti-cancer effects; it attenuates the PI3K/Akt/mTOR signaling pathway, enhances AMPK phosphorylation, downregulates FASN/SREBP2, induces apoptosis, G2/M phase arrest, and autophagy in prostate cancer cells, interferes with dihydrotestosterone-receptor binding, enhances radiation-induced DNA damage, stimulates endoplasmic reticulum stress, alleviates hepatic oxidative stress, regulates hepatic metabolic pathways, and modulates the expression of genes and proteins related to hepatic lipid metabolism, and can be used for research related to prostate cancer and alcoholic liver injury.
IC50 & Target LNCaP cells:47 μM, PC3 cells:45 μM
体外研究
(In Vitro)

Monascuspiloin (compound MP) (5-200 μM; 24-48 h) 对人雄激素依赖性 LNCaP 细胞和雄激素非依赖性 PC-3 前列腺癌细胞的活力均具有抑制作用,且效力相近,其对两种细胞的 IC50 值分别为 44.97 μM 和 46.96 μM。
Monascuspiloin (50 μM; 6-48 h) 可诱导人雄激素依赖性 LNCaP 前列腺癌细胞出现亚 G0/G1 期累积,并诱导人雄激素非依赖性 PC-3 前列腺癌细胞发生 G2/M 期阻滞。
Monascuspiloin (50 μM; 48 h) 可通过半胱天冬酶激活优先诱导人雄激素依赖性 LNCaP 前列腺癌细胞发生凋亡,而对人雄激素非依赖性 PC-3 前列腺癌细胞仅能微弱诱导凋亡。
Monascuspiloin (50 μM; 6-48 h) 可通过抑制 Akt/mTOR 通路诱导人雄激素依赖性 LNCaP 前列腺癌细胞发生凋亡,同时通过激活 AMPK 通路诱导人雄激素非依赖性 PC-3 前列腺癌细胞发生自噬性和凋亡性细胞死亡。
Monascuspiloin (50 μM; 48 h) 可选择性诱导人雄激素非依赖性 PC-3 前列腺癌细胞发生自噬性细胞死亡,从而使细胞对凋亡敏感,而在人雄激素依赖性 LNCaP 前列腺癌细胞中仅诱导极少量自噬。
Monascuspiloin (MP) (5-45 μM; 48 h) 可呈浓度依赖性降低人前列腺癌 PC-3 细胞的活力。
Monascuspiloin (15-25 μM; 联合 ionizing radiation) 可增强人前列腺癌 PC-3 细胞的放射敏感性,与单独电离辐射相比可降低克隆形成存活率。
Monascuspiloin (25 μM; 48 h) 可增强电离辐射诱导的人前列腺癌 PC-3 细胞 DNA 损伤,相较于单独使用任意一种处理方式,其导致的彗星尾长显著增加;可诱导人前列腺癌 PC-3 细胞发生内质网应激;抑制 Akt/mTOR 信号通路;诱导发生自噬;与电离辐射联合作用时,上述效应会显著增强。

Cell Viability Assay

Cell Line: human androgen-dependent LNCaP prostate cancer cells, human androgen-independent PC-3 prostate cancer cells
Concentration: 5, 25, 50, 100, 200 μM
Incubation Time: 24 h; 48 h
Result: Significantly decreased cell viability in both LNCaP and PC-3 cells in a concentration- and time-dependent manner.
Exhibited IC50 values of 44.97 μM for LNCaP cells and 46.96 μM for PC-3 cells after 48 h of treatment.

Cell Cycle Analysis

Cell Line: human androgen-dependent LNCaP prostate cancer cells, human androgen-independent PC-3 prostate cancer cells
Concentration: 50 μM
Incubation Time: 12, 24, 48 h
Result: Raised sub-G0/G1 population and reduced G0/G1 and G2/M fractions in LNCaP cells at 24 h and 48 h.
Slightly elevated sub-G0/G1 proportion and triggered prominent G2/M cell cycle arrest in PC-3 cells across 12 h, 24 h and 48 h.
Upregulated cyclin B and phosphorylated cdc2 in PC-3 cells in a time-dependent manner with no such change in LNCaP cells.

Western Blot Analysis

Cell Line: human androgen-dependent LNCaP prostate cancer cells, human androgen-independent PC-3 prostate cancer cells
Concentration: 50 μM
20 μM Z-VAD-FMK (MS-L66221)
Incubation Time: 6, 12, 24, 48 h; 1 h (Z-VAD-FMK pretreatment)
Result: Triggered time-dependent apoptosis in LNCaP cells verified by DNA fragmentation, elevated Annexin V positivity, activated caspase-3, upregulated pro-apoptotic Bax/Bad and downregulated anti-apoptotic Bcl-2/Bcl-xl.
Pretreatment with Z-VAD-FMK weakened this apoptosis and rescued cell viability in LNCaP cells.
Exerted only weak pro-apoptotic effect on PC-3 cells with negligible shifts in Bax, Bad and Bcl-xl; Z-VAD-FMK failed to reverse the viability decline in PC-3 cells.

Cell Autophagy Assay

Cell Line: human androgen-dependent LNCaP prostate cancer cells, human androgen-independent PC-3 prostate cancer cells
Concentration: 50 μM; 2.5 mM 3-Methyladenine (MS-H80278)
Incubation Time: 48 h; 1 h (3-Methyladenine pretreatment)
Result: Induced autophagy in PC-3 cells, as evidenced by the presence of autophagic vacuoles via electron microscopy, increased AVOs (35% of cells after 48 h), and increased expression of LC3-II, Atg5, and Beclin 1.
Attenuated monascuspiloin-induced autophagy and apoptosis, and reversed cell viability loss in PC-3 cells when pretreated with 3-Methyladenine.
Induced minimal autophagy in LNCaP cells, with only 15% of cells showing AVOs after 48 h of treatment.

Cell Viability Assay

Cell Line: human prostate cancer PC-3 cells
Concentration: 5 μM, 15 μM, 25 μM, 35 μM, 45 μM
Incubation Time: 48 h
Result: Reduced PC-3 cell viability in a concentration-dependent manner.
Decreased cell viability to 60% at 25 μM for 48 h.
Resulted in significantly lower cell viability at 15, 25, 35, and 45 μM.

Western Blot Analysis

Cell Line: human prostate cancer PC-3 cells
Concentration: 25 μM (alone or in combination with 4 Gy ionizing radiation)
Incubation Time: 48 h
Result: Upregulated IRE1α and phosphorylated eIF2α expression relative to untreated groups as single treatment.
Amplified the upregulation of the two proteins upon combination with 4 Gy radiation, indicating aggravated ER stress.
Suppressed phosphorylation of Akt, mTOR and p70S6K alone versus untreated controls.
Strengthened the inhibitory effect on the phosphorylation of these kinases under combined 4 Gy irradiation, with total protein expression unaltered.

Cell Autophagy Assay

Cell Line: human prostate cancer PC-3 cells
Concentration: 25 μM (alone or in combination with 4 Gy ionizing radiation)
Incubation Time: 48 h
Result: Raised the proportion of acridine orange-positive AVOs to roughly 22% as single agent, matching the effect of separate 4 Gy irradiation.
Boosted the percentage of AVOs to approximately 42% under combined treatment with 4 Gy radiation, far exceeding single treatment groups.
Triggered abundant autophagic vacuoles and autolysosomes in co-treated cells without apoptotic chromatin condensation.
Upregulated LC3-II, p62/SQSTM1 and Atg5-12 expression after combined 4 Gy radiation exposure versus individual treatments.
体内研究
(In Vivo)

Monascuspiloin (compound MP) (40-120 mg/kg;腹腔注射;每周 3 次;共注射 6 次) 可通过诱导细胞凋亡和自噬,将裸鼠体内 PC-3 前列腺癌异种移植物的生长抑制 63%-74%,且未观察到毒性。
Monascuspiloin (MP) (1 mg/kg;每周 3 次;持续 2 周) 单独作用可抑制裸鼠前列腺肿瘤生长;当与 6 Gy 电离辐射联合使用时,可提升肿瘤生长抑制率,并显著延长肿瘤生长延迟时间。
Monascuspiloin (10 mg/kg;口服;每日一次;持续 6 周) 可通过改善肝功能、减轻氧化应激、调节脂质代谢、恢复肠道菌群平衡、调控肝脏代谢通路及调节肝脏基因与蛋白表达,缓解雄性昆明小鼠的酒精性肝损伤。

Animal Model: BALB/C-nu/nu nude mice (male, 5 weeks old)
Dosage: 40 mg/kg; 120 mg/kg
Administration: i.p.; 3 times weekly; 6 total injections
Result: Inhibited tumor growth dose-dependently by 63% and 74% on day 18, lengthened tumor quadrupling and growth delay time, reduced tumor weight, suppressed proliferation marker PCNA, activated apoptosis via cleaved caspase 3, upregulated multiple autophagy proteins, and caused no weight loss or evident toxicity.
Animal Model: BALB/cAnN.Cg-Foxn1nu/CrlNarl (male, 6-8 weeks old, subcutaneous injection of 2×106 PC-3 human prostate cancer cells)
Dosage: 1 mg/kg (monotherapy); 1 mg/kg (combined with 6 Gy ionizing radiation)
Administration: three times per week; 2 weeks
Result: Inhibited tumor growth by 42.5% on day 10, prolonging tumor volume quadrupling time to 20.7 days and growth delay to 10.4 days.
Enhanced antitumor effect with 6 Gy radiation to 71.4% inhibition, extending quadrupling time to 62.6 days and delay to 52.3 days.
Reduced tumor weight more effectively than single treatment alone.
Elevated LC3 and p62 levels in tumor tissues versus monotherapy groups.
Caused no weight loss and exhibited no obvious systemic toxicity.
Animal Model: Kunming mice (male, six-week-old, specific pathogen-free)
Dosage: 10 mg/kg
Administration: p.o.; daily; 6 weeks
Result: Corrected alcohol-caused weight loss and lowered elevated liver index by 13.01%.
Lowered serum TC, TG, LDL-C, ALT and AST while raising serum HDL-C.
Decreased hepatic TC, BAs, MDA and LDH, and boosted hepatic GSH, CAT, SOD and ADH.
Alleviated hepatic steatosis and ameliorated liver pathological lesions.
Elevated multiple fecal short-chain fatty acids and repaired alcohol-triggered intestinal mucosal injury.
Regulated the relative abundance of multiple intestinal flora genera.
Remodeled 75 hepatic metabolites and interfered with several key metabolic pathways.
Modulated the transcription of lipid metabolism, detoxification, antioxidant and inflammatory-related genes.
Upregulated LDLr, CPT-1, Nrf-2, NQO1 and HO-1 protein expression and suppressed SREBP-1 protein level.
性状 固体
颜色 Yellow to orange

化学信息

分子量 360.44
分子式 C21H28O5
CAS No. 1011244-19-1
别名 Monascinol

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础